ArriVent BioPharma, Inc.
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
AVBP | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 18 CAMPUS BLVD., NEWTOWN SQUARE
- Website:
- https://arrivent.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ArriVent BioPharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
